Aranesp® (darbepoetin alfa) |
||
| Aranesp® is used to treat anaemia that comes about because of chronic renal failure (kidney failure), or to treat anaemia in cancer patients who are receiving chemotherapy. Anaemia is when your blood does not contain enough red blood cells.
|
||
Neulasta® (pegfilgrastim) |
||
| Neulasta® is used following chemotherapy to help fight infection.
|
||
NEUPOGEN® (Filgrastim) |
||
| NEUPOGEN® (Filgrastim) NEUPOGEN® is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs in doses not usually requiring bone marrow transplantation. NEUPOGEN® is indicated for reducing the duration of neutropenia and clinical sequelae in patients undergoing induction and consolidation chemotherapy for acute myeloid leukaemia.
|
||
Nplate® (romiplostim) |
||
| Nplate® is used to treat low blood platelet counts in people with immune (idiopathic) thrombocytopenic purpura (called ITP). ITP is a disease in which your immune system destroys your platelets.
|
||
Sensipar® (cinacalcet HCl) |
||
Sensipar® is used to treat:
|
||
Vectibix® (panitumumab) |
||
| Vectibix® is used in the treatment of metastatic carcinoma (cancer which has spread) of the colon (large bowel) or rectum (the back passage) after failure of chemotherapy (medicines used to treat cancer).
|
||
Prolia® (denosumab) |
||
| Prolia® is used to treat osteoporosis in women after the menopause, to reduce the risk of spinal, non-spinal and hip fractures.
Bone is a living tissue and is renewed all the time. In women, the ovaries produce the hormone oestrogen which helps keep bones healthy. After menopause, the oestrogen level drops which affects the bone renewal cycle so that more bone is lost than made, resulting in a lower bone mass. This leaves bones thin and fragile and may eventually lead to a condition called osteoporosis. Many women with osteoporosis have no symptoms but they are still at risk of breaking bones (developing fractures), especially in the spine, hips and wrists. Prolia® contains the active substance denosumab, which is a protein (monoclonal antibody) that specifically attaches (binds) to another unique protein in the body in order to treat osteoporosis and bone loss. Treatment with Prolia® makes bones stronger and less likely to break. Because Prolia® works for a long time, it is given once every 6 months. |
||
XGEVA® (denosumab) |
||
| Xgeva® is used to prevent serious bone complications caused by bone metastasis or bone lesions, such as fracture, pressure on the spinal cord or the need to receive radiation therapy or surgery.
Xgeva® contains the active substance denosumab, which is a protein (monoclonal antibody) that attaches (binds) specifically to another unique protein in the body in order to slow down bone destruction caused by cancer spreading to the bone (bone metastasis or bone lesions). |
||
Total of 8 Products |
